Pharmerging Market Pharmerging Market Poised for Rapid Growth Amid Rising Healthcare Demands US, NY, UNITED STATES, March 15, 2025 /EIN ...

We recently published a list of 10 Deep Value Stocks to Buy Now. In this article, we are going to take a look at where ...

The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

Amgen’s biosimilar formulation is distinct from both the Regeneron patent covering Eylea and from the other biosimilars at issue in litigation that’s been consolidated in a West Virginia federal court ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

To revive Tamil Nadu’s maritime heritage and position the state as a global hub for shipbuilding, the Finance Minister ...

The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars ...